BioCancell Surges Most in Three Months on Cancer Trial Results
BioCancell Therapeutics Inc. (BICL) jumped the most in three months after the biotechnology company said the results of ovarian cancer trials for its BC-819 treatment support the expansion of the clinical trials.
The shares advanced as much as 8.8 percent, the biggest gain since Dec. 11, to 0.84 shekel. It was at 0.82 shekel at 2:25 p.m. in Tel Aviv, giving the Jerusalem-based company a market value of 32.3 million shekels ($8.5 million).
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org